摘要
目的探讨AFP(甲胎蛋白)联合CA19-9(糖链抗原)检查对原发性肝癌、转移性肝癌、肝硬化、病毒性肝炎的鉴别诊断价值。方法采用全自动电化学发光系统对300例各类肝病患者及50例健康对照者进行血清AFP和CA19-9检查。结果原发性肝癌患者AFP值(838.5±175.4)μg/L较其他患者明显增高,而肝硬化患者AFP中度升高,病毒性肝炎和转移性肝癌患者AFP仅轻度升高。当以AFP>500μg/L作为原发性肝癌诊断界值时,其灵敏度为70.3%,特异性为98.8%。转移性肝癌患者CA19-9值(1265.8±113.4)U/ml较原发性肝癌、肝硬化、病毒性肝炎患者明显增高。结论 AFP联合CA19-9检测在原发性肝癌和转移性肝癌,以及对其他良恶性肝病的鉴别诊断具有良好的价值。
Objective To investigate the clinical value of using both AFP and CA19-9 as diagnostic markers to distinguish primary hepatic carcinoma, secondary hepatic carcinoma, hepatic cirrhosis and viral hepatitis. Methods 300 patients and 50 healthy control subjects were studied.An automatic electro-chemiluminescence system was used to evaluate the level of serum AFP and CAl9-9.Results The level of AFP in patients with primary hepatic carcinoma （838.5±175.4）μg/L was higher than the patients with other diseases.AFP was moderately elevated in patients with hepatic cirrhosis and only slightly increased in patients with viral hepatitis and secondary hepatic carcinoma.Using the cut off value of 500 μg/L, the sensitivity and specificity of using AFP for the diagnosis of primary hepatic carcinoma was 70.3% and 98.8%, respectively. The level of CA19-9（ 1265.8±113.4）U/mL is higher in patients with secondary hepatic carcinoma than with the primary hepatic carcinoma, hepatic cirrhosis or viral hepatitis. Conclusion Both AFP and CA19-9 should be used as biomarkers to distinguish primary hepatic carcinoma, secondary hepatic carcinoma and other hepatic diseases.
出处
《热带医学杂志》
CAS
2009年第12期1420-1421,1426,共3页
Journal of Tropical Medicine
关键词
甲胎蛋白
糖链抗原
鉴别诊断
alpha fetal protein
carbohydrate antigen 19-9
differential diagnosis
